@TerekAdrian

Patient Advocate. Knowledge Dispersion. #ClinicalTrials LifeTrials - Coming Soon. Dont let the perfect become the enemy of the good

Joined May 2020
  • Tweets497
  • Following476
  • Followers197
40Media
Thank you Laure for representing COLONTOWN at ESMO! Looking forward to hearing all that you have to share.
Laure Chotel@LaureChotel8 Sep 2022
I am excited to attend #ESMO22 @myESMO as a Patient Advocate to represent #colorectal #cancer patients & caregivers around the world with our wonderful @colontown community! @fireflyann @manjuggm @TerekAdrian
1
4
Next #CRCTrialsChat is on BRAFmCRC! Great to have Dr @VanMorrisMD as the guest moderator along with our #MedOnc mods, Drs. @jonathanloree & @aparna1024 📌For #RadOnc POVs :Drs. @NiuSanford & @KrishanJethwa & 📌For #surgery POVs :Drs. @sepideh_gholami & @AGangiMD!! Don't miss👇👇
1
8
1
17
I have about 10 patients I can put on this trial yesterday!
Adrian Terek@TerekAdrian29 Jun 2022
It would be hard to overstate how exciting these early results are in late-line MSS CRC patients without liver involvement. From non existent ORR in nearly all IO only trials, to 42% in those without liver involvement. I highly look forward to future results and confirmation!
1
2
Adrian Terek retweeted
A.n.n.@fireflyann30 Jun 2022
Good news!!! @rene @TerekAdrian
Aparna Raj Parikh@aparna102429 Jun 2022
Stay tuned. Compelling data. Will be opening the p2 and running an investigator initiated study soon.
1
2
Replying to @OncoAlert
@OncoAlert @ESMOWorldGI Impact of Next Gen CTLA4i Botensilimab in MSS metastatic CRC is promising. Bot/Bal led to 24% ORR (10/41 patients), 73% of disease control, median DOR not reached. In patients without liver mets, ORR 42 % ! @ODayMD @DrMhidalgo @DrElkhoueiry
1
2
1
5
Future potential for more aggressive liver-directed therapy to "clear the way" for IO based approaches?
Bruno Bockorny MD
@BrunoBockorny30 Jun 2022
Replying to @OncoAlert
@OncoAlert @ESMOWorldGI Impact of Next Gen CTLA4i Botensilimab in MSS metastatic CRC is promising. Bot/Bal led to 24% ORR (10/41 patients), 73% of disease control, median DOR not reached. In patients without liver mets, ORR 42 % ! @ODayMD @DrMhidalgo @DrElkhoueiry
3
It would be hard to overstate how exciting these early results are in late-line MSS CRC patients without liver involvement. From non existent ORR in nearly all IO only trials, to 42% in those without liver involvement. I highly look forward to future results and confirmation!
Aparna Raj Parikh@aparna102429 Jun 2022
Stay tuned. Compelling data. Will be opening the p2 and running an investigator initiated study soon.
1
3
1
9
A standard metric after therapeutic trials should be the responses to the question: “would you — the oncologist — recommend this treatment for you or your family if affected by this disease?” Patients are the ultimate stakeholders because it’s their lives on the line! #ASCO22
5
12
1
104
Laro in NTRK fusion primary CNS tumors. More evidence that it works. We can't treat patients with this drug if we don't test their tumors for the fusions!! Let's make NGS the standard of care for patients with primary brain tumors! #btsm #asco22
2
9
Small but mighty! This is a video of a killer T cell of the immune system destroying a monstrous ovarian cancer cell. I recently captured this data on a spinning disc confocal microscope.
875
13,075
2,606
64,482
Adrian Terek retweeted
#TrialsChat@CRCchat15 Apr 2022
Replying to @pikospeaks @manjuggm @TerekAdrian
Hi Nancy, thank you for joining and for @paltown1 support of this activity! Read & learn more about @paltown1 & their awesome programs, here paltown.org/ COLONTOWN University, their newest venture is certainly worth a visit. learn.colontown.org/ #CRCtrialsChat
2
3
The #CRCTrialsChat would not have been possible without @paltown1 support & for Nancy's (@pikospeaks) enthusiasm for all the projects I propose🤣😂 #CRCSM
Nancy Seybold@pikospeaks15 Apr 2022
Replying to @CRCchat @CRCTrialsChat
Hi everyone, I’m Nancy Seybold, Co-founder and COO of PALTOWN, the nonprofit that manages the COLONTOWN community and sponsor of this TweetChat! Many thanks to @manjuggm and @TerekAdrian for kicking this off!
2
3
Adrian Terek retweeted
rene@ReneFromMd15 Apr 2022
I wish sponsors would be a bit more flexible. I don't understand why I can't just have blood drawn either at my local center or with LabCorp. I did that when I was going to trial at Hopkins and it worked out great. It really allowed me to live my life and participate on the trial
2
3
2
6
Adrian Terek retweeted
#TrialsChat@CRCchat15 Apr 2022
Thanks to our amazing moderators Drs @aparna1024, @jonathanloree @NiuSanford & @KrishanJethwa for joining us! Thanks to Dr @manjuggm & @TerekAdrian for their perspectives on trials! Thanks to everyone who joined despite their busy lives! Hopefully this was helpful! #CRCTrialsChat
#TrialsChat@CRCchat15 Apr 2022
Thank you all for an hour of teaching & learning! Let us know if this was helpful. “Moments” of this TweetChat will be available here next week. A blogpost with highlights will be available on CTU. Mark your calendars for May 12 7:00 PM CST, tell your friends.. #CRCTrialsChat
1
3
1
7
Adrian Terek retweeted
#TrialsChat@CRCchat15 Apr 2022
Thank you all for an hour of teaching & learning! Let us know if this was helpful. “Moments” of this TweetChat will be available here next week. A blogpost with highlights will be available on CTU. Mark your calendars for May 12 7:00 PM CST, tell your friends.. #CRCTrialsChat
1
2
1
5
Thank you everyone for participating in the inaugural #CRCTrialsChat A special thank you to the moderators for the generous contribution of their time and expertise. Looking forward to the next one!
2
Adrian Terek retweeted
#TrialsChat@CRCchat15 Apr 2022
A11. This vitally imp question deserves its own session! Tune in on May 12 7:00 PM CST for our exciting information session that you cannot miss! We will introduce 2 awesome Trial finders See U then! Meanwhile, visit CTU Clinical Trials LC learn.colontown.org/learning… #CRCTrialsChat
3
4
A10.5 Doctors have become very skilled at clinical trial design that optimizes patient safety. Strict safety protocols ensure that patient safety is the number one priority for everyone involved. #CRCTrialsChat
3
4
Adrian Terek retweeted
#TrialsChat@CRCchat15 Apr 2022
Q 10.3 Myth or Fact? : "Clinical trials are a last resort" #CRCTrialsChat #CRCSM #colorectalcancer
1
2
A10.3 Myth BUSTED! Patients who enroll in clinical trials have better outcomes than those who dont. @NCCN & @ASCO recommend trial participation at every stage of treatment #CRCTrialsChat
1
1
Load more